Indian Paediatricians Urged to Comply with the Infant Milk Substitutes Act
The Indian Academy of Paediatrics (IAP), the largest association of paediatricians in India, has issued a critical reminder to its members regarding compliance with the Infant Milk Substitutes (IMS) Act. This follows a recent controversy involving Abbott Nutrition, which sponsored a national paediatric summit in Dehradun.
In an email circulated to all members, IAP emphasized that the IMS Act prohibits involvement from not only manufacturers of infant milk substitutes and foods but also those engaged in their marketing, sales, and distribution. This alert comes as the Breastfeeding Promotion Network of India (BPNI) raised concerns over the summit, urging IAP to caution members against participation.
Legal Implications and Member Responsibilities
BPNI’s national convenor, Nupur Bidla, highlighted that violations of the IMS Act could result in criminal charges. Complaints have been filed with local authorities, and BPNI is seeking action against any doctors participating in the Abbott-sponsored event, citing section 6.8 related to doctor-industry relationships.
The IAP has reiterated its commitment to upholding the law. The organization has advised its members to thoroughly vet sponsors and contributors for any ties to the IMS Act and to secure written assurances confirming their compliance.
Importance of Compliance for Child Welfare
IAP’s statement underlines the importance of adhering to laws that protect child welfare. As new companies emerge, particularly those producing baby foods, the need for vigilance is paramount. Doctors are encouraged to ensure that their engagements do not conflict with regulations designed to safeguard children’s health.
For more insights and updates on health regulations, visit Looffers.com.
